Fundz

Chemomab to acquire Scipher Medicine Corporation

PUBLIC · CMMBOct 01, 2026

Acquiring Company

Chemomab Therapeutics Ltd

Acquired Company

Scipher Medicine

Tel AvivWalthamBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareMedicalTherapeutics

Description

Chemomab Therapeutics Ltd. has executed an amendment to its merger agreement with Scipher Medicine Corporation. This amendment revises the terms of the domestication merger, ensuring that Chemomab will redomicile to the U.S. and that Scipher will become a wholly-owned subsidiary. The transaction is expected to close in Q4 2026, with the combined company anticipated to list on Nasdaq under a new ticker.

Company Information

Company

Chemomab Therapeutics Ltd

Location

KIRYAT ATIDIM, BUILDING 7

Tel Aviv, Tel Aviv District, Israel

About

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing. For more information on Chemomab, visit chemomab.com.

Fundz sees it the moment Chemomab Therapeutics Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Adi
Likely contact at this company
••••••••@••••••••

See Adi's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Chemomab Therapeutics Ltd's next move

Learn about Strategic plan

Frequently asked

Who acquired Scipher Medicine?

Scipher Medicine was acquired by Chemomab Therapeutics Ltd, based in Tel Aviv. The deal was reported on October 1, 2026. Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Chemomab Therapeutics Ltd is publicly traded (CMMB) and operates in Biotechnology.

When did Chemomab Therapeutics Ltd acquire Scipher Medicine?

Chemomab Therapeutics Ltd's acquisition of Scipher Medicine was reported on October 1, 2026. Chemomab Therapeutics Ltd. has executed an amendment to its merger agreement with Scipher Medicine Corporation. This amendment revises the terms of the domestication merger, ensuring that Chemomab will redomicile to the U.S. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Scipher Medicine do?

Scipher Medicine, a precision immunology company matching patients with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. It is privately held, operating in Biotechnology, and is based in Waltham.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.